C. Baum

发表

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

C. Antonescu, J. Fletcher, G. Demetri, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Farnesyl Transferase Inhibitors: Mechanism of Action, Translational Studies and Clinical Evaluation

W. R. Bishop, C. Baum, P. Kirschmeier, 2003, Cancer biology & therapy.

A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)

C. Fuchs, H. Lenz, D. Ryan, 2005 .

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST)

J. Manola, G. Demetri, R. Badawi, 2005 .

Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)

R. Motzer, M. Michaelson, B. Redman, 2005 .

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

G. Demetri, M. Heinrich, P. Casali, 2005 .

Preclinical and clinical evaluation of farnesyltransferase inhibitors

C. Baum, P. Kirschmeier, 2003, Current oncology reports.

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

J. Manola, J. Desai, J. Folkman, 2007, Clinical Cancer Research.

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

R. Figlin, R. Motzer, M. Michaelson, 2006 .

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

C. Baum, B. Gumbiner, S. Fazio, 2018, Cardiovascular therapeutics.

Implantation and maintenance of functional human bone marrow in SCID-hu mice.

J. McCune, C. Baum, R. Namikawa, 1992, Blood.

Analysis of candidate human blood stem cells in "humanized" immune-deficiency SCID mice.

I. Weissman, C. Baum, B. Péault, 1993, Leukemia.

Implantation and maintenance of functional human bone marrow in SCID-hu mice

J. McCune, C. Baum, R. Namikawa, 1992 .

Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248

J. Desai, G. Demetri, J. Heymach, 2005 .

Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression.

C. Baum, A. Farese, T. MacVittie, 2000, Blood.

The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2&Dgr;a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

C. Baum, J. Pons, B. Gumbiner, 2018, Cardiovascular therapeutics.

Cell surface antigens expressed by subsets of pre-B cells and B cells.

C. Baum, J. Mckearn, J. Davie, 1984, Journal of immunology.

Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor.

C. Baum, J. McKearn, A. Farese, 1996, Blood.

Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia.

C. Baum, A. Farese, T. MacVittie, 1996, Blood.

Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3.

C. Baum, J. Monahan, M. Abrams, 1995, Proceedings of the National Academy of Sciences of the United States of America.

cytokine (SC-55494) after radiation-induced bone marrow aplasia Acceleration of hematopoietic reconstitution with a synthetic

C. Baum, A. Farese, T. MacVittie, 2011 .

Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3.

L. Tye, H. Lenz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.

A. D. Van den Abbeele, J. Manola, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).

M. Michaelson, J. Sosman, B. Rini, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance.

G. Demetri, J. Verweij, P. Casali, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thy-1-expressing CD34+ human cells express multiple hematopoietic potentialities in vitro and in SCID-hu mice.

I. Weissman, C. Baum, A. Tsukamoto, 1993, Nouvelle revue francaise d'hematologie.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

H. Rugo, A. Wolff, H. Burstein, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST

J. Blay, G. Demetri, A. Cesne, 2007 .

CD 34 + Progenitor Cells From Asymptomatic Patients Are Not a Major Reservoir for Human Immunodeficiency Virus-l

C. Baum, William, F. Villinger, 2002 .

CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.

C. Baum, J. Wingard, W. Fleming, 1995, Blood.

Mobilization of peripheral-blood stem cells by concurrent administration of daniplestim and granulocyte colony-stimulating factor in patients with breast cancer or lymphoma.

J. Winter, J. Dipersio, C. Baum, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mobilization o f P eripheral-Blood S tem C ells b y C oncurrent Administration o f D aniplestim a nd G ranulocyte Colony-Stimulati ng F actor i n P atients W ith Breast C ancer o r L ymphoma

J. Winter, J. Dipersio, C. Baum, 2000 .

Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST.

J. Blay, G. Demetri, S. George, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.

G. Demetri, H. Hurwitz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B Cell Subsets and Differential Responses to Mitogens

J. Paslay, C. Baum, J. Slack, 1982, Immunological reviews.

H. Wildiers, C. Baum, S. Dychter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.

R. Figlin, R. Motzer, M. Michaelson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma

R. Motzer, J. Beaumont, D. Cella, 2005 .

Polymorphism of Fc receptor on murine B cells is Igh-linked

C. Baum, R. Riblet, J. Mckearn, 1985, The Journal of experimental medicine.

Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST

G. Demetri, J. Verweij, P. Casali, 2007 .

model of radiation-induced myelosuppression stimulates multilineage hematopoietic recovery in a nonhuman primate Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist,

C. Baum, A. Farese, T. MacVittie, 2013 .

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).

A. D. Van den Abbeele, J. Fletcher, G. Demetri, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

7501 ORAL Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing

J. Blay, G. Demetri, A. Cesne, 2007 .

Monoclonal antibodies specific for novel murine cell surface markers define subpopulations of germinal center cells.

C. Baum, F. Platt, J. Cebra-Thomas, 1992, Cellular immunology.

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).

C. Baum, C. Peschel, N. Vogelzang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mobilization of dendritic cells in cancer patients treated with granulocyte colony‐stimulating factor and chemotherapy

C. Baum, A. Roberts, D. Ashley, 2002, British journal of haematology.

Today's SCID-hu mouse

J. McCune, C. Baum, A. Tsukamoto, 1990, Nature.

Characterization and Enrichment of Candidate Human Hematopoietic Stem Cells

I. Weissman, C. Baum, A. Tsukamoto, 1993 .

Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)

H. Rugo, H. Burstein, M. Collier, 2005 .

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

John Smeraglia, R. Motzer, M. Michaelson, 2007, Journal of Translational Medicine.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2007, The New England journal of medicine.

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Xin Huang, Patrick Schöffski, G. Demetri, 2009, Clinical Cancer Research.

Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

C. Baum, P. Kirschmeier, A. Taveras, 2003, Current topics in medicinal chemistry.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Xin Huang, J. Desai, G. Demetri, 2006, The Lancet.

Isolation of a candidate human hematopoietic stem-cell population.

I. Weissman, C. Baum, A. Tsukamoto, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Lymphoid reconstitution of the human fetal thymus in SCID mice with CD34+ precursor cells

I. Weissman, J. McCune, C. Baum, 1991, The Journal of experimental medicine.

Sunitinib in patients with metastatic renal cell carcinoma.

R. Motzer, J. Bacik, M. Michaelson, 2006, JAMA.

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

L. Tye, H. Lenz, D. Ryan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

Xin Huang, C. Baum, L. Rosen, 2009, Clinical Cancer Research.

Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

A. Scott, C. Baum, G. O'Keefe, 2012, EJNMMI Research.

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

A. D. Van den Abbeele, C. Antonescu, J. Fletcher, 2009, Clinical Cancer Research.

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

F. Kabbinavar, C. Baum, C. Britten, 2008, Cancer Chemotherapy and Pharmacology.

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.

C. Antonescu, J. Fletcher, G. Demetri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypothyroidism may accompany SU11248 therapy in a subset of patients (pts) with metastatic (met) gastrointestinal stromal tumors (GIST) and is manageable with replacement therapy

Ming-Hui Chen, J. Desai, G. Demetri, 2005 .

Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin.

L. Kanz, R. Möhle, W. Brugger, 2000, Experimental hematology.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

J. Desai, G. Demetri, J. Verweij, 2006, The Lancet.

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

M. Kattan, R. Figlin, R. Motzer, 2008, Cancer.

Clinical-scale production of granulocyte progenitor and post-progenitor cells using daniplestim, leridistim, Progenipoietin, Promegapoietin and autologous plasma.

J. Winter, E. Papoutsakis, C. Baum, 2000, Cytotherapy.

Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells.

L. Kanz, B. Meister, W. Brugger, 2000, Experimental hematology.

Study of the DBA/2Ha immunodeficiency: X-chromosome mosaicism and in vivo immunoresponses.

C. Baum, M. Nahm, K. Macke, 1987, Immunology letters.

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

Patrick Schöffski, Paolo G. Casali, G. Demetri, 2008 .

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST).

A. D. Van den Abbeele, M. Bertagnolli, G. Demetri, 2006, Journal of Clinical Oncology.

Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy

J. Desai, G. Demetri, S. George, 2005 .

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST

J. Manola, J. Desai, G. Demetri, 2005 .

human granulocyte colony-stimulating factor nonhuman primates using synthokine SC-55494 and recombinant Combination therapy for radiation-induced bone marrow aplasia in

C. Baum, T. MacVittie, F. Hérodin, 2011 .

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis

J. Blay, G. Demetri, A. Cesne, 2008 .

Abstract 13322: The Effects of Single Dose Administration of RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects Treated with and without Atorvastatin

C. Baum, J. Pons, B. Gumbiner, 2012 .

Abstract 13524: The Effects of Multiple Dose Administration of RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects

C. Baum, J. Pons, B. Gumbiner, 2012 .

Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival

R. Motzer, M. Michaelson, B. Redman, 2007 .

A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).

R. Motzer, G. V. Kondagunta, M. Ginsberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

L. Tye, H. Lenz, D. Ryan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2007, The New England journal of medicine.

Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients

R. Motzer, M. Michaelson, B. Rini, 2009, Journal of Translational Medicine.

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer.

H. Burstein, M. Collier, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.